Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Gross Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Gross Margin for 16 consecutive years, with 59.71% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 265.0% to 59.71% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 57.67% through Dec 2025, down 51.0% year-over-year, with the annual reading at 57.67% for FY2025, 51.0% down from the prior year.
  • Gross Margin for Q4 2025 was 59.71% at Harvard Bioscience, up from 58.38% in the prior quarter.
  • The five-year high for Gross Margin was 61.2% in Q1 2023, with the low at 45.21% in Q3 2022.
  • Average Gross Margin over 5 years is 56.99%, with a median of 57.2% recorded in 2021.
  • The sharpest move saw Gross Margin plummeted -977bps in 2022, then skyrocketed 1285bps in 2023.
  • Over 5 years, Gross Margin stood at 59.17% in 2021, then dropped by -6bps to 55.7% in 2022, then rose by 4bps to 57.99% in 2023, then fell by -2bps to 57.06% in 2024, then grew by 5bps to 59.71% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 59.71%, 58.38%, and 56.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.